Trial reportScientific reports2025
Lactococcus cremoris YRC3780 improves subjective stress response in the Uchida-Kraepelin test: a randomized, double-blind, placebo-controlled study.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kefir Consumption and Health Effects Based on Human Clinical Trials: An Overview of Literature.Healthcare (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactococcus cremoris YRC3780, isolated from kefir, likely improves the hypothalamic-pituitary-adrenal axis response to acute psychological stress by acting on intestinal immune cells and promoting cytokine production. Here we examined the effectiveness of YRC3780 on the stress response in healthy Japanese adults. We investigated the effects of daily YRC3780 intake on the stress response in a randomized, placebo-controlled, double-blind, parallel-group study of 107 healthy Japanese adults (54 in the YRC3780 group and 53 in the placebo group) who had an initial positive Uchida-Kraepelin (U-K) test stress response. After 8 weeks, the POMS2 Total Mood Disturbance (TMD) score after the U-K test and the change in score from baseline score were significantly better in the YRC3780 group than in the placebo. The YRC3780 group showed significant improvements in the POMS2 TMD and in five POMS2 subscores difference before and after the U-K test at 8 weeks. Daily YRC3780 intake significantly improved the stress response in healthy Japanese adults who had an initial stress response in the U-K test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.